* INVO Bioscience Inc INVO.OQ reported a quarterly adjusted
loss of 17 cents per share for the quarter ended in June. The
mean expectation of two analysts for the quarter was for a loss
of 19 cents per share.
* Revenue was $208.00 thousand; analysts expected $409.50
thousand.
* The mean earnings estimate of analysts had fallen by
about 15.2% in the last three months.
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company.
* INVO Bioscience Inc shares had fallen by 8.8% this quarter and
gained 40.9% so far this year.
* Wall Street's median 12-month price target for INVO Bioscience
Inc is $5.88
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
This summary was machine generated August 16 at 09:54 p.m. All
figures in US dollars unless otherwise stated